Physician profile
Richard Carpenter
NPI 1376600486
$1,154.87
in general payments reported to CMS, 2019-2025
24 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $106 · 2021: $15.88 · 2022: $39.59 · 2023: $101 · 2024: $258 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $261.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $167.99 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $106.69 | 2019-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $74.35 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.38 | 2024-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $44.15 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $42.95 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $41.68 | 2019 | |
| Abbvie INC. | $41.39 | 2022-2024 | |
| Shire North American Group INC | $36.31 | 2019 | |
| Dexcom, INC. | $30.78 | 2025 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $29.29 | 2020 | |
| Merck Sharp & Dohme LLC | $27.30 | 2019-2025 | Gardasil 9, Capvaxive |
| Mylan Specialty L.P. | $25.97 | 2019-2020 | |
| Viatris Specialty LLC | $24.08 | 2025 | Yupelri |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $20.73 | 2019 | |
| Abbott Laboratories | $18.21 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.74 | 2025 | Caplyta |
| Amgen INC. | $16.22 | 2024 | Repatha, Otezla |
| Allergan, INC. | $14.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.47 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.78 | 2019 | |
| Pfizer INC. | $13.06 | 2019 | |
| Sanofi Pasteur INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.